

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>JUN 2 3 2004</i></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
Sheet <i>1</i> of <i>2</i>				Application Number	09/835,523
				Filing Date	04/17/2001
				First Named Inventor	Yong-Qian Wu
				Group Art Unit	1624
				Examiner Name	Truong, Tamthom Ngo
				Attorney Docket Number	054707-0661

U.S. PATENT DOCUMENTS						<i>Class/Subclass</i>
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
TNT	A1	4,801,706		WINKLEY et al.	01/31/1989	540/534
	A2	5,399,565		GREENWOOD et al.	03/21/1995	514/314
	A3	5,670,503		KAWAI et al.	09/23/1997	514/343
	A4	5,798,355		STEINER et al.	08/25/1998	514/248

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
TNT	A5	CA	2,271,837 ✓	A1	ARZNEIMITTEL WERK DRESDEN GMBH, DE	11/11/1999	_____
	A6	EP	0 104 484 ✓	A1	NIPPON KAYAKU KABUSHIKI KAISHA	04/04/1984	_____
	A7	EP	0 450 757 ✓	A2	GLAXO GROUP LIMITED	10/09/1991	_____
	A8	EP	0 778 023 ✓	A1	AMERICAN HOME PRODUCTS CORPORATION	06/11/1997	_____
	A9	WO	89/06535 ✓	A1	E.R. SQUIBB & SONS, INC.	07/27/1989	_____
	A10	WO	94/19350 ✓	A1	FUJISAWA PHARMACEUTICAL CO., LTD.	09/01/1994	_____
	A11	WO	99/20272 ✓	A1	MERCK & CO., INC.	04/29/1999	_____
	A12	WO	96/05180 ✓	A1	ABBOTT LABORATORIES	02/22/1996	_____
	A13	WO	99/462481 ✓	A1	VERTEX PHARMACEUTICALS INCORPORATED	09/16/1999	_____
TNT	A14	WO	98/05333 ✓	A1	MOLECUMETICS LTD	02/12/1998	_____

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁶
TNT	A15	BALDWIN et al., "Pyrazolotriazines: a new class of tumour-inhibitory agents," J. Pharm. Vol. 18, pp. 1S-4S (May 2, 1966).				
TNT	A16	Borloo et al., "Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase," Letters in Peptide Science, vol. 2, pp. 198-202 (1995).				

Examiner Signature	<i>Wilson</i>	Date Considered	3/18/05
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>JUN 23 2004</p> <p>(use as many sheets as necessary)</p> <p>Sheet 1 of 2</p>			<p>Complete if Known</p> <table border="1"> <tr> <td>Application Number</td> <td>09/835,523</td> </tr> <tr> <td>Filing Date</td> <td>04/17/2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Yong-Qian Wu</td> </tr> <tr> <td>Group Art Unit</td> <td>1624</td> </tr> <tr> <td>Examiner Name</td> <td>Truong, Tamthom Ngo</td> </tr> <tr> <td>Attorney Docket Number</td> <td>054707-0661</td> </tr> </table>		Application Number	09/835,523	Filing Date	04/17/2001	First Named Inventor	Yong-Qian Wu	Group Art Unit	1624	Examiner Name	Truong, Tamthom Ngo	Attorney Docket Number	054707-0661
Application Number	09/835,523															
Filing Date	04/17/2001															
First Named Inventor	Yong-Qian Wu															
Group Art Unit	1624															
Examiner Name	Truong, Tamthom Ngo															
Attorney Docket Number	054707-0661															

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
TNT	A17	STEINER et al., "Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A," Nature Medicine, vol. 3, no. 4, pp. 421-428 (April 1997).		

Examiner Signature		Date Considered	3/18/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.